TABLE 2.
Subgroup analysis of PFS and OS between patients in IO+C and C groups
| Subgroup | PFS (months) | OS (months) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IO + C | C | IO + C | C | |||||||||
| n | mPFS | 95% CI | n | mPFS | 95% CI | p‐value | mOS | 95% CI | mOS | 95% CI | p‐value | |
| Gender | 0.1 | 0.003 | ||||||||||
| Female | 13 | 6.0 | 5.2–6.8 | 12 | 3.9 | 1.4–6.4 | 12.8 | 3.2–22.4 | 11.6 | 8.2–15.1 | ||
| Male | 7 | 8.0 | 3.0–12.9 | 8 | 2.8 | 1.1–4.5 | 12.3 | 10.5–14.1 | 10.4 | 2.5–18.3 | ||
| Age | 0.04 | 0.003 | ||||||||||
| <65 | 17 | 6.1 | 2.9–9.2 | 15 | 2.8 | 0–5.7 | 12.7 | 10.9–14.4 | 10.5 | 8.7–12.3 | ||
| ≥65 | 3 | 7.3 | 5.8–8.8 | 5 | 3.9 | 1.2–6.6 | 19.4 | 6.9–32.0 | 6.2 | 0–20.0 | ||
| Smoker | 0.09 | ‐ | ||||||||||
| No | 15 | 6.4 | 4.7–8.0 | 17 | 2.8 | 0.5–5.1 | 12.8 | 10.6–15.0 | 10.5 | 8.6–12.4 | ||
| Yes | 5 | 8.0 | 2.9–13.1 | 3 | 9.1 | NR | 23.2 | NR | 7.8 | NR | ||
| ECOG | 0.04 | 0.003 | ||||||||||
| 0–1 | 15 | 6.4 | 4.3–8.5 | 14 | 2.8 | 0.8–4.8 | 12.3 | 10.5–14.1 | 10.4 | 4.6–16.2 | ||
| 2–3 | 5 | 8.0 | 3.9–12.1 | 6 | 2.2 | 0–8.3 | 21.5 | 2.9–40.1 | 2.3 | 6.0–15.1 | ||
| EGFR mutation | ||||||||||||
| Exon19 del mutation | 9 | 8.0 | 1.0–14.9 | 8 | 2.8 | 1.9–3.7 | 0.07 | 19.7 | 2.5–36.9 | 10.4 | 8.2–12.6 | |
| Exon20 T790M mutation | 6 | 5.6 | 5.2–6.1 | 7 | 4.3 | 3.3–5.3 | 0.08 | 11.0 | 10.3–11.7 | 10.67 | 0.8–20.5 | |
| Exon21 L858R mutation | 10 | 6.4 | 4.5–8.3 | 11 | 3.9 | 0.02–7.8 | 0.09 | 11.6 | 9.6–13.6 | 10.5 | 5.0–16.1 | |
| Liver metastasis | 0.02 | 0.004 | ||||||||||
| No | 13 | 7.3 | 5.0–9.6 | 14 | 4.3 | 1.3–7.3 | 12.7 | 1.9–23.5 | 10.7 | 9.2–12.1 | ||
| Yes | 7 | 6.4 | 1.6–11.1 | 6 | 2.0 | 1.7–2.3 | 12.8 | 9.1–16.5 | 6.8 | 0–13.7 | ||
| Brain metastasis | 0.2 | 0.006 | ||||||||||
| No | 10 | 10.1 | 4.6–15.6 | 9 | 3.9 | 0–8.6 | 19.4 | 5.3–33.6 | 10.5 | 2.1–18.9 | ||
| Yes | 10 | 5.6 | 5.0–6.3 | 11 | 2.8 | 0.5–5.1 | 12.7 | 10.2–15.1 | 10.7 | 9.0–12.4 | ||
| Bone metastasis | 0.09 | 0.006 | ||||||||||
| No | 6 | 8.0 | 0.1–15.9 | 4 | 2.0 | 0.2–3.7 | 29.8 | 3.3 | 0.6–6.0 | |||
| Yes | 14 | 6.1 | 5.4–6.7 | 16 | 2.8 | 0.02–5.6 | 12.7 | 11.0–14.3 | 10.7 | 9.1–12.2 | ||
| Adrenal metastasis | 0.03 | 0.002 | ||||||||||
| No | 15 | 6.1 | 5.1–7.0 | 16 | 3.9 | 1.2–6.6 | 12.8 | 3.5–22.1 | 11.6 | 9.6–13.6 | ||
| Yes | 5 | 10.1 | 5.6–14.6 | 4 | 1.7 | 0.8–2.7 | 12.3 | 10.3–14.3 | 3.1 | 0.4–5.8 | ||
| Platinum‐based regimens | 0.01 | 0.009 | ||||||||||
| No | 12 | 6.1 | 5.4–6.7 | 7 | 2.0 | 1.9–2.1 | 11.6 | 9.6–13.6 | 11.6 | 9.6–13.7 | ||
| Yes | 8 | 7.3 | 2.5–12.1 | 13 | 5.7 | 1.0–10.3 | 19.4 | 8.9–30.0 | 9.5 | 5.8–13.3 | ||
| Line of combination therapy | 0.05 | 0.004 | ||||||||||
| Third | 12 | 7.3 | 4.5–10.0 | 13 | 3.9 | 1.0–6.8 | 19.4 | 3.7–35.2 | 10.7 | 8.7–12.6 | ||
| Fourth or beyond | 8 | 5.6 | 5.0–6.3 | 7 | 2.8 | 1.2–4.4 | 12.3 | 9.2–15.4 | 9.5 | 5.2–13.9 | ||
Abbreviations: C, chemotherapy; EGFR, epidermal growth factor receptor; IO+C, immunotherapy plus chemotherapy; OS, overall survival; PFS, progression‐free survival.